{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:19:08Z","timestamp":1787318348954,"version":"build-2736575974"},"reference-count":86,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"supported by the Medical University of Lodz through grants","award":["503\/1-093-01\/503-11-004"],"award-info":[{"award-number":["503\/1-093-01\/503-11-004"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/17460441.2023.2236547","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T01:59:43Z","timestamp":1689213583000},"page":"1065-1076","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-5415","authenticated-orcid":false,"given":"Pawe\u0142","family":"Robak","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Witkowska","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wolska-Washer","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"issue":"3","key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/cancers14030771","article-title":"The role of Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions","volume":"14","author":"Robak T","year":"2022","unstructured":"Robak T, Witkowska M, Smolewski P. The role of Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions. Cancers (Basel). 2022 Feb 2;14(3):771.","journal-title":"Cancers (Basel)"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1384814"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694853"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116358"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-109973"},{"issue":"10","key":"e_1_3_4_11_1","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak E","year":"2022","unstructured":"Robak E, Robak T. Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J Clin Med. 2022 May 16;11(10):2807.","journal-title":"J Clin Med"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1130595"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051504"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT132"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2144218"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00857-8"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140172"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123331"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01482-5"},{"key":"e_1_3_4_23_1","unstructured":"https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?tab=clinical&ligandId=10629."},{"key":"e_1_3_4_24_1","volume-title":"24th Annual Meeting of the CSCO","author":"Song Yuqin DL","year":"2021","unstructured":"Song Yuqin DL, Zhang B, Luo H, et al. Preliminary results of orelabrutinib concentrations in peripheral blood and cerebrospinal fluid in patients with relapsed\/refractory primary or secondary CNS lymphoma. 24th Annual Meeting of the CSCO, September 25, 2021, Beigene, 2021."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031205"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.03.015"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04473-5"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159944"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26826"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146491"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134531"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126305"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141781"},{"key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"101682","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao XX","year":"2022","unstructured":"Cao XX, Jin J, Fu CC, et al. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine. 2022;52:101682.","journal-title":"EClinicalMedicine"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.753"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.133"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165710"},{"key":"e_1_3_4_40_1","doi-asserted-by":"crossref","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","article-title":"Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series","volume":"12","author":"Yang C","year":"2022","unstructured":"Yang C, Cui Y, Ren X, et al. Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol. 2022;12:901797.","journal-title":"Front Oncol"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159383"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843788.10370.07"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-345"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.06.007"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000121"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01764-1"},{"key":"e_1_3_4_49_1","unstructured":"https:\/\/www.innocarepharma.com\/en\/media\/press-release\/20220812\/."},{"key":"e_1_3_4_50_1","unstructured":"https:\/\/www.innocarepharma.com\/en\/media\/press-release\/20220906\/."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e449"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2598"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov189"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01219-5"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01072-6"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00209-1"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01295-3"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2188103"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18418"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061336"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1435268"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0063"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127674"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18162"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125488"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123680"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170985"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01318-8"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140806"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080764"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00235-X"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1409"},{"key":"e_1_3_4_85_1","doi-asserted-by":"crossref","unstructured":"Woyach J Flinn IW Awan FT et al. Nemtabrutinib (MK-1026) a non-covalent inhibitor of wild-type and C481S mutated Bruton Tyrosine Kinase for B-cell malignancies: efficacy and safety of the phase 2 dose-expansion BELLWAVE-001 study. Presented At: 2022 EHA Congress; cited Jun 9-12 2022; Vienna Austria. Abstract P682. https:\/\/bit.ly\/3HDw2fC","DOI":"10.1097\/01.HS9.0000845612.25766.0c"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00491"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2023.2236547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T10:16:48Z","timestamp":1695205008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2023.2236547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/17460441.2023.2236547"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2023.2236547","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}